The article discusses how Western drug makers are seeking alternative suppliers in response to draft U.S. legislation that would restrict working with certain Chinese biotechs. These Chinese companies produce active pharmaceutical ingredients for many U.S. and European drugmakers, prompting companies like Eli Lilly and Vertex Pharmaceuticals to diversify production. In other news, European regulators found no evidence linking GLP-1 drugs like Ozempic and Wegovy to suicidal thoughts or actions after a nine-month investigation. The review was initiated following anecdotal reports of patients experiencing self-harm thoughts while on these medications. Overall, the article highlights the current developments in the pharmaceutical industry.
Source link
AstraZeneca CEO pay, alternatives to WuXi and more
